We found that target molecules of these inhibitors, including VEGFR1, VEGFR2, VEGFR3, VEGFA and PDGFRB, were markedly expressed only in cancer 1 and 2 clusters (primary tumor and LN metastasis), while their expressions in cancer 4 (bone metastasis) and CSC clusters were relatively low (Supplementary Fig. S9A). The gene discussed is PDGFRB; the disease is neoplasm.